ESC 365 - Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

HFA Premium Access

Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

Session: Cardiomyopathies: present and future

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor M. Lima (Lisbon, PT)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Maria Rita Lima

Hospital Santa Cruz, Lisbon (Portugal)

1 follower

4 more presentations in this session

DPD quantification correlates with ECV and disease severity in transthyretin cardiac amyloidosis

Speaker: Doctor R. Rettl (Vienna, AT)

ATTRibute-CM: ITT sensitivity analysis and sub-analysis comparing acoramidis and placebo in stage 4 CKD

Speaker: Professor S. Poulsen (Aarhus N, DK)

Temporality of events leading to the diagnosis of obstructive hypertrophic cardiomyopathy (oHCM): a machine learning approach using UK retrospective data

Speaker: Mr M. Hurst (London, GB)

Delayed diagnosis of hypertrophic cardiomyopathy: results from electronic medical records analysis

Speaker: Doctor C. Mao (San Francisco, US)

Access the full session

Cardiomyopathies: present and future

Speakers: Doctor M. Lima, Doctor R. Rettl, Professor S. Poulsen, Mr M. Hurst, Doctor C. Mao

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources